Dr Philippe Halfon and colleagues from France evaluated the test performance profile of blood tests of liver fibrosis.
The research team assessed 356 patients with chronic Hepatitis C in 2 centers.
Metavir staging of liver specimens was conducted by 2 independent pathologists.
The team evaluated the Fibrotest, aspartate aminotransferase to platelet ratio index, FibroMeter, and Hepascore.
|Metavir stage 1 was identified in 55% of patients|
|Journal of Hepatology|
The team found metavir stage 0 in 4%, stage 1 in 55%, stage 2 in 26%, stage 3 in 11%, and stage 4 in 4% of patients.
The researchers observed that the area under the receiving-operating-characteristic were not significantly different.
The test performance profile relies on the paired comparison of blood-test misclassification based on liver specimen.
The research team observed no center effect.
Dr Halfon's team concludes, “In those populations, the 4 blood tests had a similar performance for significant fibrosis in stage 2.”
“The tests lay in the lower range of published results, which is attributable to a low stage 2 prevalence, and for stage 3 and 4.”
“However, the FibroMeter and Fibrotest had performance profiles significantly different as a function of fibrosis stages or diagnostic target.”
“This has to be considered during the interpretation process.”
“Moreover, the performance should be reported with different diagnostic targets.”